Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
Kazuya Ofuji(Chiba Cancer Center), Tetsuya Nakatsura(Unknown), Toshiaki Yoshikawa(Aichi Cancer Center), Yoshitaka Tada, Naoto Gotohda(Shizuoka Cancer Center), Daisuke Nobuoka(Fukuyama City Hospital), Manami Shimomura(National Cancer Center Hospital East), Shiro Suzuki(National Cancer Center Hospital East), Masaru Konishi(Shizuoka Cancer Center), Yasunari Nakamoto(University of Fukui), Shinichiro Takahashi(Shizuoka Cancer Center), Yu Sawada(Yokohama City University), Keigo Saito, Mayuko Yoshimura(Chiba Cancer Center), Mari Takahashi(Chiba Cancer Center), Hirofumi Shirakawa(Shizuoka Cancer Center), Nobuhiro Tsuchiya(Yokohama City University)
Cited by 28
Related Papers
Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer
|British journal of surgery|2018|401
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Long‐term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: a multi‐institutional Japanese study
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|267
Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition
|Journal of Hepato-Biliary-Pancreatic Sciences|2020|235
The Tokyo 2020 terminology of liver anatomy and resections: Updates of the Brisbane 2000 system
|Journal of Hepato-Biliary-Pancreatic Sciences|2021|184